Literature DB >> 31631158

[A Case Altered Consciousness Due to 5-Fluorouracil-Induced Hyperammonemia in a Patient with Recurrent Colorectal Cancer].

Sho Sawazaki1, Masakatsu Numata, Mihwa Ju, Junya Morita, Keisuke Komori, Yukio Maezawa, Shinya Amano, Toru Aoyama, Hiroshi Tamagawa, Tsutomu Sato, Takashi Oshima, Hiroyuki Mushiake, Norio Yukawa, Munetaka Masuda, Yasushi Rino.   

Abstract

We report a case of altered consciousness related to hyperammonemia due to FOLFIRI plus bevacizumab therapy in a patient with recurrent colorectal cancer and renal dysfunction.A 76-year-old man received third-line chemotherapy for left mediastinal lymph node metastasis.He complained of diarrhea on the evening of the same day, and mental confusion on day 3 of the first FOLFIRI therapy.He had a JCS of Ⅲ(200).The laboratory results revealed a marked hyperammonemia.5 - fluorouracil(5-FU)-induced hyperammonemia was diagnosed and the patient was ventilated and managed with branchedchain amino acid solutions, lactulose, and hemodialysis in the ICU.After hemodialysis, the blood ammonia level reduced to the normal limits, and the symptoms of encephalopathy resolved on the following day.He was discharged home on the 19th day of hospitalization.5 -FU-containing therapy should be carefully administered in patients with renal dysfunction.Herein, we report a case of 5-FU-induced hyperammonemia with literature considerations.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31631158

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses.

Authors:  Yoshinao Ozaki; Hirotaka Imamaki; Aki Ikeda; Mitsuaki Oura; Shunsaku Nakagawa; Taro Funakoshi; Shigeki Kataoka; Yoshitaka Nishikawa; Takahiro Horimatsu; Atsushi Yonezawa; Takeshi Matsubara; Motoko Yanagita; Manabu Muto; Norihiko Watanabe
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-03       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.